FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer By Ogkologos - June 27, 2025 550 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ARANOTE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma October 26, 2023 Cancer and the Holidays December 3, 2021 Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... February 16, 2023 Good News and Cautions about Pregnancy for Childhood Cancer Survivors March 4, 2022 Load more HOT NEWS Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... Latest episode of our podcast for researchers ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular... EMA Recommends Granting a Conditional Marketing Authorisation for Dostarlimab
